![OGSIVEO FDA-Approval Featured Image](https://dtrf.org/wp-content/uploads/2023/11/breaking-news-niro-FDA-approval-featured-image-2-720x450.png)
Featured News
FDA APPROVES OGSIVEO™ (NIROGACESTAT), AS THE FIRST MEDICAL THERAPY FOR THE TREATMENT OF ADULTS WITH PROGRESSING DESMOID TUMORS.
Filter by:
![2023 DTRF "Together We Will" Weekend](https://dtrf.org/wp-content/uploads/2023/11/TWW-email-banner-720x450.png)
November 3, 2023
DTRF Hosts the 2023 “Together We Will” Weekend in Philadelphia
Read More about DTRF Hosts the 2023 “Together We Will” Weekend in Philadelphia
![](https://dtrf.org/wp-content/uploads/2023/11/jeanne-1600-100-720x450.jpg)
October 30, 2023
Reflections From Jeanne Whiting, Our Retiring Executive Director And DTRF’s Co-Founder
![](https://dtrf.org/wp-content/uploads/2023/11/press-release-1200-facebook-linkshare-720x450.jpg)
October 1, 2023
Ten New ICD-10-CM Diagnosis Codes For Desmoid Tumors Go Into Effect on October 1, 2023, in the United States.
![](https://dtrf.org/wp-content/uploads/2023/11/DTAM-collage-with-badge-2023-720x450.jpg)
September 30, 2023
Desmoid Tumor Awareness Month 2023 Comes To A Close
Read More about Desmoid Tumor Awareness Month 2023 Comes To A Close
![](https://dtrf.org/wp-content/uploads/2023/09/press-release-1200-720x450.jpg)
September 26, 2023
DTRF Press Release: The Desmoid Tumor Research Foundation Announces That Groundbreaking Results From The Phase 3 Springworks Defi Trial Were Published Today In The New England Journal Of Medicine (More)
![ASCO 2023](https://dtrf.org/wp-content/uploads/2023/11/ASCO-2023-posters-100-720x450.jpg)
June 12, 2023